Charlene Banard, Shire Pharmaceuticals’ Senior Vice President of Global Quality, spoke at the 2016 edition of the Biomanufacturing World Summit. In this presentation she shares her thoughts and experiences on maintaining an effective quality focus in operations during mergers and acquisitions.
- Discussing best practices to establish and maintain a quality focus on each product lifecycle during M&A activity
- Clarifying who is responsible for what and opening up lines of communication, coordination, and collaboration between teams in transition
- Balancing phase appropriate applications of quality systems, knowledge and risk management, and product control
- Offering examples of positive outcomes and explaining what made these stories a success
Charlene Banard is accountable for the global Quality function at Shire, a global biotechnology company focused on meeting unmet medical needs of patients with rare diseases and specialty conditions. In partnership with her colleagues at Shire, Charlene and her team provide a safe and ready supply of quality products and services to our patients and healthcare providers. Charlene has more than 25 years in the biopharmaceutical industry bringing new products and technologies to fruition through robust team partnerships. Prior to joining Shire, she held leadership positions at Gilead Sciences, Cell Genesys and Chiron Corporation. She holds a Bachelor of Science degree in Biochemistry from the University of California, Davis and a Masters in International Business from Saint Mary’s College in Moraga, California.